Recently, several studies revealed outstanding progress in the diagnosis of SFT based on a fusion gene of juxtaposed NGFI-A binding protein 2 (NAB2) and signal transducer and activator of transcription 6 (STAT6) using both whole-exome sequencing and integrative sequencing [4–6]. The gene discussed is NAB2; the disease is solitary fibrous tumor.